Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	28.87	28.36	34.81	29.43	39.14
Short-Term Investments	489.7	696.93	388.78	275.52	369.11
Cash & Short-Term Investments	518.57	725.28	423.6	304.95	408.25
Cash Growth	-28.50%	71.22%	38.91%	-25.30%	109.98%
Receivables	2.02	0.7	2.63	0.35	0.17
Prepaid Expenses	14.08	21.18	5.47	12.39	2.42
Total Current Assets	534.66	747.16	431.69	317.69	410.84
Property, Plant & Equipment	7.77	8.24	6.64	7.75	6.52
Other Intangible Assets	27.19	27.19	27.19	27.19	27.19
Other Long-Term Assets	13.36	9.75	0.11	0.1	0.1
Total Assets	582.98	792.34	465.63	352.74	444.65
Accounts Payable	1.18	3.27	3.49	3.34	1.23
Accrued Expenses	47.03	33.84	22.03	12.84	12
Current Portion of Leases	1.55	1.45	1.61	1.45	1.75
Current Unearned Revenue	1.23	0.01	3.06	0.06	0.43
Other Current Liabilities	-	0.93	0.93	0.93	1.12
Total Current Liabilities	50.99	39.5	31.13	18.61	16.53
Long-Term Leases	0.78	2.36	0.93	2.59	1.3
Long-Term Unearned Revenue	2.43	-	-	-	-
Long-Term Deferred Tax Liabilities	1.61	-	-	-	-
Other Long-Term Liabilities	-	3.47	4.4	5.33	7.35
Total Liabilities	55.82	45.34	36.46	26.53	25.18
Common Stock	0.07	0.07	0.06	0.05	0.05
Additional Paid-In Capital	2,337	2,299	1,823	1,581	1,561
Retained Earnings	-1,814	-1,555	-1,397	-1,256	-1,144
Comprehensive Income & Other	3.63	3.31	3.31	1.26	1.89
Shareholders' Equity	527.17	747.01	429.17	326.2	419.48
Total Liabilities & Equity	582.98	792.34	465.63	352.74	444.65
Total Debt	2.34	3.81	2.54	4.03	3.04
Net Cash (Debt)	516.24	721.47	421.06	300.92	405.21
Net Cash Growth	-28.45%	71.35%	39.92%	-25.74%	112.22%
Net Cash Per Share	7.77	11.20	8.69	6.42	9.45
Filing Date Shares Outstanding	66.57	66.38	55.9	47.21	46.74
Total Common Shares Outstanding	66.55	66.37	55.88	47.2	46.73
Working Capital	483.67	707.66	400.57	299.08	394.31
Book Value Per Share	7.92	11.25	7.68	6.91	8.98
Tangible Book Value	499.98	719.82	401.98	299.01	392.29
Tangible Book Value Per Share	7.51	10.84	7.19	6.33	8.39
Machinery	17.18	17.39	16.01	15.26	14.51
Construction In Progress	1.72	0.14	0.79	0.5	0.63
Leasehold Improvements	10.34	10.29	9.65	9.61	9.53

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q